Table 3.
Transplant outcomes for patients that underwent allogeneic stem cell transplantation in the retrospective and prospective study
| Neutrophil engraftment | Platelet engraftment | Grades 2–4 acute GVHD | Chronic GVHD at 4 years | Relapse at 4 years | NRM at 4 years | LFS at 4 years | OS at 4 years | ||
|---|---|---|---|---|---|---|---|---|---|
| Retrospective study group (n = 339) | |||||||||
| MSDT (n = 99) | MRDneg (group A) | 98% (95% CI, 96–100%) | 98% (95% CI, 94–100%) | 9% (95% CI, 3 to 15%) ‡, ## | 58% (95% CI, 45 to 71%) | 11% (95% CI, 4 to 18%) | 16% (95% CI, 7 to 25%) | 73% (95% CI, 63 to 83%) | 76% (95% CI, 66 to 86%) |
| MRDpos (group B) | 93% (95% CI, 79–100%) £ | 93% (95% CI, 79–100%) | 7% (95% CI, 0 to 21%) †, # | 66% (95% CI, 35 to 97%) | 60% (95% CI, 22 to 98%) | 7% (95% CI, 0 to 21%) | 33% (95% CI, 2 to 64%) | 33% (95% CI, 2 to 64%) | |
| Haplo-SCT (n = 240) | MRDneg (group C) | 99% (95% CI, 99–100%) | 99% (95% CI, 97–100%) | 36% (95% CI, 29 to 43%) | 48% (95% CI, 40 to 56%) | 15% (95% CI, 10 to 20%) | 14% (95% CI, 9 to 19%) | 71% (95% CI, 65 to 77%) | 75% (95% CI, 69 to 81%) |
| MRDpos (group D) | 98% (95% CI, 96–100%) | 97% (95% CI, 93–100%) | 43% (95% CI, 29 to 57%) | 70% (95% CI, 56 to 84%) * | 19% (95% CI, 5 to 33%) | 8% (95% CI, 1 to 15%) | 73% (95% CI, 58 to 88%) | 75% (95% CI, 60 to 90%) | |
| Prospective study group (n = 340) a | |||||||||
| MSDT (n = 82) | MRDneg (group E) | 98% (95% CI, 95–100%) | 98% (95% CI, 94–100%) | 10% (95% CI, 2 to 17%) $, $$ | 56% (95% CI, 39 to 72%) | 7% (95% CI, 0 to 13%) | 5% (95% CI, 0 to 11%) | 88% (95% CI, 79 to 97%) | 94% (95% CI, 87 to 100%) |
| MRDpos (group F) | 95% (95% CI, 85–100%) ££ | 95% (95% CI, 85–100%) | 5% (95% CI, 0 to 15%) ††, ‡‡ | 41% (95% CI, 20 to 62%) | 36% (95% CI, 14 to 58%) | 16% (95% CI, 0 to 33%) | 48% (95% CI, 25 to 71%) | 64% (95% CI, 42 to 86%) | |
| Haplo-SCT (n = 258) | MRDneg (group G) | 99% (95% CI, 99–100%) | 99% (95% CI, 99–100%) | 28% (95% CI, 21 to 35%) | 40% (95% CI, 31 to 49%) | 7% (95% CI, 3 to 11%) | 18% (95% CI, 12 to 24%) | 75% (95% CI, 69 to 81%) | 78% (95% CI, 72 to 84%) |
| MRDpos (group H) | 97% (95% CI, 91–100%) | 98% (95% CI, 94–100%) | 32% (95% CI, 20 to 44%) | 73% (95% CI, 52 to 94%) ** | 13% (95% CI, 4 to 22%) | 7% (95% CI, 0 to 14%) | 80% (95% CI, 69 to 91%) | 83% (95% CI, 73 to 93%) | |
The differences in any of the transplant outcomes between the four groups were analyzed with a log-rank test
Abbreviations: GVHD graft-versus-host disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, MRD minimal residual disease, MSDT human leukocyte antigen-matched sibling donor transplantation, MRDpos MRD positive, MRDneg MRD negative, Haplo-SCT haploidentical stem cell transplantation
£ P < 0.01 compared with group D
££ P < 0.05 compared with group D
‡ P < 0.05 compared with group C
## P < 0.01 compared with group D
† P < 0.05 compared with group C
# P < 0.01 compared with group D
*P = 0.980 compared with group B
$ P < 0.01 compared with group G
$$ P < 0.01 compared with group H
†† P < 0.05 compared with group G
‡‡ P < 0.05 compared with group H
**P = 0.223 compared with group F
aIndicates the transplant outcomes of patients in the prospective study are listed as chronic GVHD, relapse, NRM, LFS and OS at 2 years